drugset / Trial / NCT00745511

Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)

NCT00745511 ↗

Phase 1/2 Unknown 96 enrolled Ora Bio Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is s randomized, multi-center, double blind, 3 arm, phase I/II pilot study to evaluate the safety and efficacy of treatment with ORA102 combined with Avastin (Bevacizumab) versus Avastin alone, in patients with neo-vascular age related macular degeneration (AMD).

Timeline

Start
2009-03
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody 1.25 mg Intravitreal
Comparator Disulfiram Small molecule — Intravitreal

Indications